Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Ovarian Cancer
  Fallopian Tube Cancer
• Age: Between 18 years - 100 years
• Gender: Female

• Other Inclusion Criteria:
  

  1) Recurrent, platinum resistant ovarian cancer 2) 1-2 prior regimens (including primary therapy) 3) Measurable disease or evaluable disease
  

You may not be eligible for this study if the following are true:

• 1) Patients who have had systemic anticancer therapy (e.g., chemotherapy, targeted therapy) within 3 weeks prior to entering the study. 2) Patients who have had hormonal therapy (e.g., tamoxifen, aromatase inhibitor) within 1 week prior to entering the study. 3) Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents. 4)Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to Cycle 1, Day 1.